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INK4 and CIP/KIP are two distinct families of cyclin-dependent kinase (CDK) inhibitors implicated in
mediating a wide range of cell growth control signals. We have created p18INK4c-deficient mice. These mice
develop gigantism and widespread organomegaly. The pituitary gland, spleen, and thymus are
disproportionately enlarged and hyperplastic. T and B lymphocytes develop normally in p18-deficient mice,
but both exhibit increased cellularity and a higher proliferative rate upon mitogenic stimulation. Loss of p18,
like that of p27, but not other CDK inhibitor genes, leads to a gradual progression from intermediate lobe
pituitary hyperplasia in young mice to an adenoma by 10 months of age with a nearly complete penetrance.
Mice lacking both p18 and p27, like mice chimeric for Rb deficiency, invariably died from pituitary adenomas
by 3 months. Hence, p18 and p27 mediate two separate pathways to collaboratively suppress pituitary
tumorigenesis, likely by controlling the function of Rb.
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To exert an effect on cell proliferation, most cell growth
regulatory pathways must interact with the machinery
that controls progression through the G1 phase of the
cell cycle. These pathways range from growth-activating
events such as fertilization or mitogenic stimulation to
growth-inhibitory signals like DNA damage, cell differ-
entiation, or senescence. How these individual pathways
interact at the molecular level with the G1 cell cycle
control pathway is largely unknown (Pardee 1989; Sherr
1994). The eukaryotic cell cycle is regulated primarily by
a family of serine/threonine protein kinases, consisting
of regulatory cyclin subunits and catalytic cyclin-depen-
dent kinase (CDK) subunits (for review, see Hunter and
Pines 1994; Morgan 1995). In mammalian cells, two
CDK enzymes, CDK4 or CDK6 in combination with
three D-type cyclins (D1, D2, and D3), and CDK2 in
association with cyclin E, play distinct key roles in regu-
lating G1 progression. CDK4/6–cyclin D couple extra-
cellular growth signals to the cell cycle, while CDK2–
cyclin E controls the initiation of DNA replication (Sherr
1994). In contrast to the role of cyclins in mediating mi-
togenic stimulatory signals, CDK inhibitors are respon-
sible for integrating many growth-inhibitory pathways.
The expression of CDK inhibitor genes has been found to
be induced by or correlated with a wide range of growth-
inhibitory signals, such as mitogen starvation, cell–cell
contact inhibition, DNA damage, antiproliferative cyto-
kine treatment, terminal differentiation, and senes-
cence, implicating CDK inhibitors in coupling diverse
cell signaling pathways to the cell cycle machinery
(Sherr and Roberts 1995).
The seven mammalian CDK inhibitor genes identified
thus far belong to two separate families. The INK4
family includes four closely related ankyrin repeat
containing genes: p16INK4a, p15INK4b, p18INK4c, and
p19INK4d, and the CIP1/KIP1 family contains three
genes: p21CIP1/WAF1, p27KIP1, and p57KIP2 (Sherr and
Roberts 1995). INK4 proteins selectively form binary
complexes with CDK4 or CDK6 to prevent the CDKs
from binding with and becoming activated by D-type
cyclins. p21/p27/p57 inhibitors broadly regulate mul-
tiple CDK enzymes, including CDK4/6–cyclin Ds, by
forming ternary complexes with CDK and cyclin pro-
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teins. These features make CDK4 and CDK6 unique
among the members of the CDK family as the only
CDKs regulated by both CIP/KIP and INK4 families of
inhibitors, and broaden the ability of CDK4 and CDK6 to
serve as integrators for the convergence of many growth
control signaling pathways.
While the biochemical mechanism(s) by which CDK
inhibitors regulate CDK activity is relatively well under-
stood, most functional studies on CDK inhibitors were
carried out in cultured cells and are largely correlative.
To address this issue, a genetic approach has been taken
to determine the function of CDK inhibitors by gene
targeting. Despite common CDK targets shared by both
families of CDK inhibitor proteins, no obvious pheno-
typic similarities have been observed thus far for any of
the four CDK inhibitor genes that have been genetically
disrupted. Mice lacking p21 are defective in a DNA-dam-
age mediated G1 checkpoint, but are developmentally
normal and do not develop spontaneous tumors (Deng et
al. 1995). Disruption of p16 (and its colocalized p19ARF)
results in the development of spontaneous tumors at an
early age in numerous cell types (Serrano et al. 1996).
Mice lacking p57 die soon after birth, displaying severe
developmental defects with a varying degree of pen-
etrance and phenotype similar to human patients with
Beckwith–Wiedemann syndrome (Zhang et al. 1997; Yan
et al. 1997). Disruption of p27 in mice results in a series
of additional novel phenotypes including increased body
size, multiorgan hyperplasia, female sterility, retinal
dysplasia, and pituitary tumors (Fero et al. 1996; Ki-
yokawa et al. 1996; Nakayama et al. 1996). These effects
argue a diverse range of functions for the different CDK
inhibitor genes.
We previously isolated a member of the INK4 gene
family, p18INK4c, and showed that, like p16, ectopic ex-
pression of p18 in cultured cells suppresses cell growth
with correlated dependence on endogenous wild-type
pRB (Guan et al. 1994). The p18 gene is widely expressed
during mouse embryogenesis and accumulates to high
levels in a number of terminally differentiated tissues
and during cell aging (Guan et al. 1994; Franklin and
Xiong 1996; Zindy et al. 1997; Phelps and Xiong 1998).
Here, we report that mice lacking p18 exhibit a series of
phenotypes remarkably similar to those seen in mice
lacking p27, including development of widespread or-
ganomegaly, pituitary hyperplasia and adenoma, and a
hyperproliferative response to mitogenic stimulation.
The progression of pituitary tumors in mice lacking both
p18 and p27 is greatly accelerated compared with either
single gene disruption, indicating a functional collabora-
tion between these two CDK inhibitors.
Results
Targeted deletion of the mouse p18 gene
We disrupted the mouse p18-coding region by homolo-
gous recombination (Fig. 1A; Material and Methods).
The mouse p18 gene contains three exons: exon 1 corre-
sponding exclusively to the 58-untranslated region and
two coding exons, exons 2 and 3 (Phelps et al. 1998). The
majority (75%) of the p18-coding region is contained in
exon 3 (amino acid residues 42–168), and was targeted for
deletion. In the targeting construct, a 2-kb EcoRI geno-
mic fragment containing exon 3 was replaced with a neor
cassette (Fig. 1A). After electroporation and selection of
neomycin-resistant foci, two heterozygous p18+/− ES
clones (C5 and C55) were identified by Southern blot-
ting. Both ES clones were karyotyped normal and micro-
injected into C57BL/6 blastocysts to generate germ-line
chimeras. Three male F1 chimeras derived from ES clone
C55 successfully mated with B6D2/F1J females to pro-
duce F2 heterozygote offspring harboring the mutant
INK4c allele. The F2 heterozygotes were mated to pro-
duce the F3 founder p18
+/+, p18+/− and p18−/− strains. All
genotypes were verified by Southern blotting (Fig. 1B)
and confirmed further by examination of the expression
of p18 protein (Fig. 1C). No obvious difference in the
level of p18 protein was detected between wild-type and
heterozygous animals. Deletion of exon 3 generates a
mutant INK4c allele that retains a small portion of p18
coding for the amino-terminal 41 residues of the p18
protein. The p18 antibody we used was raised against a
carboxyl terminus peptide, preventing us from firmly ex-
cluding the possibility that the remaining 41 residues are
expressed or could still bind to and interfere with the
function of CDK4 and CDK6. However, this possibility
seems very unlikely as deletion of the fourth ankyrin
repeat in p16 (residue 110, corresponding to residue 102
at the carboxyl terminus in p18) completely abolished
binding of p16 with CDK4 (Yang et al. 1995). Also, mis-
sense mutations of several residues in the third ankyrin
repeat of p18 (e.g., Arg-79 and Asp-100), which are de-
leted in our p18-deficient mice, completely abolished
binding of p18 and its inhibitory activity toward CDK4/
CDK6 (S. Noh, Y. Li, Y. Xiong, and K.-L. Guan, unpubl.).
p18-null mice have increased body size
and exhibit organomegaly
Mating of p18 heterozygous mice produced wild-type,
heterozygous, and null pups in essentially the antici-
pated Mendelian ratio (18:32:17), indicating that p18 het-
erozygous and null embryos are viable. p18-null mice
undergo normal development well into adulthood. Ex-
cept for the pituitary tumor described below, we did not
detect any increased rate of tumorigenesis in p18-null
mice ranging from 1 to 13 months (n = 30), indicating
that in most tissues, p18 alone may have only a limited
or redundant role in tumor suppression. While previous
studies correlated induced p18 expression and associa-
tion with CDK4 and CDK6 during in vitro myogenesis
and adipogenesis (Franklin and Xiong 1996; Phelps and
Xiong 1998), we did not detect abnormal muscle or adi-
pose development in p18-null animals, This indicates
that p18 does not have an essential role in causing cell
cycle withdrawal during the differentiation of these two
tissues. Whether p18 plays a role in maintaining the cell
cycle arrest in mature myotubes or adipocytes remains
to be determined. Both male and female p18−/− animals
Franklin et al.
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are fertile and can mate successfully with wild-type or
null animals. Litter number (88 litters for p18+/+ and 81
litters for p18−/−, P = 0.336) and size (8.9 pups/litter for
p18+/+ and 9.1 pups/litter for p18−/−, P = 0.672) produced
from these different matings are similar, indicating that
lack of p18 function does not significantly impair repro-
duction.
At birth, wild-type, heterozygous, and null mice ap-
pear indistinguishable. However, within 2–3 weeks, the
p18−/− mice became distinctly larger than their p18+/+
littermates (Fig. 2A). A detailed analysis of this pheno-
type showed that as early as 9 days, p18−/− mice were
7.4% bigger than p18+/+ littermates and 35%–45% larger
by the end of 1 month (Fig. 2B). By day 33, even the
smallest p18−/− female was bigger than the largest p18+/+
male (Fig. 2C). We examined p18−/− mice externally and
internally to determine whether any organs were dispro-
portionately large with respect to their increased body
size. Externally, p18−/− mice did not show any abnormal
proportions. Internally, p18-deficient mice display wide-
spread organomegaly (Fig. 2D). We compared the relative
increase in body and organ weights between the p18-null
and wild-type mice at 1, 2, and 3 months (Fig. 2E). Three
organs, the heart, kidney, and liver, from null animals
were roughly proportionate in weight to the increase in
total body weight. However, the spleen and thymus were
disproportionately enlarged. The body weight of null
mice increased by 20%, 40%, and 30% at 1, 2, and 3
months, respectively. The weight of the spleen in p18-
null animals increased disproportionately by 40%,
110%, and 90% during the same time points. The in-
crease of thymus weight, twice the body weight increase
in p18-null animals at 1 month, became proportionate to
the body weight increase at 2 months, and was dispro-
portionately small at 3 months. These observations sug-
gest that loss of p18 function not only promotes dispro-
portionate thymus growth at an early age, but also ac-
celerates later thymic involution. Although larger than
wild-type testes (Fig. 2D,E), the testes of 1-, 2-, and 3-
month-old p18-null males were disproportionately small
with respect to the body size (Fig. 2E). Two other organs
that were difficult to weigh but showed apparent dispro-
portionate enlargement were the adrenal (Fig. 2D) and
the pituitary (see Fig. 4, below) glands.
There was no obvious difference in the levels of p18
protein between p18+/+ and p18+/− tissues (Fig. 1C). Con-
sistently, we did not observed any significant difference
in the body and organ size between p18+/+ and p18+/−
mice (data not shown), indicating that there is no gene
dose dependence for the p18 protein expression. This is
different from loss of p27 function, where p27+/− hetero-
zygotes were intermediate in size between small p27+/+
and large p27−/− homozygotes. This suggests that in vivo
p18 but not p27 protein levels are in excess for its function.
Figure 1. Targeted disruption of p18INK4c
locus. (A) Genomic structure of the mouse
INK4c locus. The mouse INK4c locus con-
tains three exons. Coding region is shown
by black boxes. The relative positions of
restriction sites and translation initiation
and termination codons are indicated. p18
was disrupted by replacement of the 2-kb
EcoRI fragment containing exon 3 with the
neor selectable marker. The 4.6- and 1.9-kb
genomic fragments used for homologous
recombination and the probe fragment used
for Southern analysis are indicated. (B)
Southern blot analysis of the p18 locus. Ge-
nomic DNA from p18+/+ (lanes 1,4), p18+/−
(lanes 2,5) and p18−/− (lanes 3,6) mice was
digested with restriction enzymes EcoRV
(lanes 1–3) or SphI (lanes 4–6) and hybrid-
ized with a p18 probe (see A). Molecular
size markers are indicated. (C) p18 protein
expression in mouse tissues. Total cell ly-
sates were prepared from several p18+/+,
p18+/−, and p18−/− tissues. Expression of
p18 protein was determined by IP–Western
blot analysis with antibodies specific for
p18. The p18 protein is indicated.
p18 and p18–p27 knockouts
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Because the p18-null mice develop evident pituitary
pathology (see below), which could produce an elevated
level of growth hormones, an increase in body and organ
size could result from endocrine abnormalities, rather
than a defect in cell cycle control. For example, trans-
genic expression of growth hormone (GH; Palmiter et al.
1982), or insulin-like growth factor I (IGF-I; Mathews et
al. 1988) results in a similar gigantism phenotype. GH or
IGF-I transgenic mice, however, display certain histopa-
thologies not detected in p18-deficient mice including
hepatic hypertrophy, glomerular sclerosis, diffuse kidney
tubular atrophy, and dermal abnormalities (Quaife et al.
1989). This observation argues against elevated growth
hormones as a possible mechanism for gigantism in p18-
deficient mice. Mice lacking p18 had normal serum level
of GH (133 ng/ml GH for p18+/+ and 62 ng/ml GH for
p18−/−, P = 0.09) and an only slight increase of IGF-I (516
ng/ml IGF-I for p18+/+ and 739 ng/ml IGF-I for p18−/−,
P = 0.11). Therefore, we believe that the gigantism and
organomegaly phenotypes resulted from an alteration in
cell cycle control resulting from the loss of p18 function
rather than endocrine effects. These observations, how-
ever, do not exclude the possibility that p18 functions
downstream of the growth hormones in certain cell types.
p18-null mice display expansion of T lymphocytes
and are hyper-responsive to mitogenic stimulation
Disproportionate enlargement of the thymus and spleen
in young p18-null animals prompted us to examine he-
matolymphoid organs from wild-type and p18-null mice.
FACS analysis showed a normal CD4+ and CD8+ T cell
distribution in the thymus, lymph nodes (Fig. 3A), and
spleen (data not shown) in p18-null animals, indicating
normal T-lymphocyte development in the absence of
p18. However, p18-null animals had a 40% increased
thymic cellularity (Fig. 3B). A decrease in apoptosis does
not seem to contribute significantly to the thymic hy-
percellularity, as apoptosis of thymocytes in response to
CD3 stimulation was normal (data not shown) and was
only slightly decreased in response to dexamethasone
(31% in wild-type and 26% in p18-null thymocytes,
P = 0.06, Fig. 3C).
To determine the effect of loss of p18 on T-lymphocyte
proliferative response to mitogenic stimulation, we ac-
tivated lymph node cells in vitro with concanavalin A
(ConA). Cells were then pulse labeled with [3H]thymi-
dine, and DNA synthesis was determined (Fig. 3D).
ConA-stimulated p18-null lymph node cells incorpo-
rated 3.1-fold more 3H than the wild-type cells. We fur-
ther evaluated the response of lymph node cells to ConA
stimulation in vivo. Twelve hours after intraperitoneal
ConA injection, lymph node cells were isolated and im-
mediately pulse labeled with [3H]thymidine. Consistent
with the in vitro stimulation, in vivo mitogen-stimu-
lated p18-deficient lymph node cells incorporated 3.3-
fold more 3H than stimulated wild-type lymph node
cells (Fig. 3D).
To provide a mechanistic explanation for the increase
of p18-null T-lymphocyte proliferation in response to
mitogenic activation, we determined the CDK4 and
CDK6 kinase activity of lymph node cells following mi-
togenic stimulation. Mice were injected with ConA, and
lymph nodes were harvested 12 hr later. CDK4 and
CDK6 immunocomplexes from lymph nodes of both
wild-type and p18-null animals were assayed for their Rb
kinase activity. While CDK4 immunocomplexes from
both wild-type and p18-null lymphocytes contained
similar levels of Rb kinase activity, CDK6 immunocom-
plexes from ConA-stimulated p18-null lymphocytes ex-
hibited a 2.5-fold higher Rb kinase activity than those
from wild-type cells (Fig. 3E). This result is consistent
Figure 2. p18-deficient mice exhibit body size increase and
organomegaly. (A) Wild-type (agouti, left) and p18-deficient
(black, right) mice at 4 weeks of age. Size is indicated in centi-
meters. (B) Growth curve of p18-deficient (j) and wild-type (h)
mice. Both genotypes (nine each) were weighed from age 9 to 63
days. Standard error bars are indicated. (C) Body weight com-
parison of male and female p18-deficient and wild-type mice.
Data were taken from B for days 33, 45, and 63 and replotted
according to gender: wild-type males (open bars), null males
(black bars), wild-type females (blue bars), and null females (red
bars). (D) Organomegaly in p18−/− mice. Gross appearance of
adrenal gland, heart, kidney, spleen, thymus, and testis are
shown for p18+/+ and p18−/− animals. (E) Increase of body and
individual organ weights in p18−/− mice relative to wild-type
littermates. p18+/+ and p18−/− animals were weighed at ages 1
month (open bars), 2 months (blue bars) and 3 months (black
bars). Heart, kidney, liver, spleen, thymus, and testis from these
mice were isolated and weighed. The data are plotted as relative
body and individual organ weight differences of the p18−/− ani-
mal compared with the p18+/+ animals.
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with the previous finding that p18 is preferentially asso-
ciated with CDK6 compared with CDK4 (Guan et al.
1994) and that CDK6 is more prominently expressed
than CDK4 in T lymphocytes (Meyerson and Harlow
1994). Increased CDK6 activity resulting from the loss of
p18 function may provide a plausible molecular mecha-
nism for the increased T-lymphocyte proliferation in re-
sponse to mitogenic activation and the thymic hypercel-
lularity seen in p18-null animals.
p18 negatively regulates cell cycle entry of resting
B lymphocytes
Enlargement of the spleen in p18-null animals led us to
examine B-lymphocyte development and their T-depen-
dent response. B cells from the spleen and bone marrow
of p18-null mice showed normal B220 and IgM distribu-
tions, indicating that B-cell development, like that of T
cells, was normal in the absence of p18 function (Fig.
4A). At 2 months, p18-null animals had increased cellu-
larity in both the spleen and bone marrow (Fig. 4B). To
determine the molecular mechanism underlying the hy-
percellularity in the spleen, we purified resting B lym-
phocytes from the spleens of wild-type or p18-null mice
and stimulated them in vitro with CD40 ligand (CD40L)
and IL-6 (see Material and Methods). The number of ac-
tivated, viable IgM+ B cells began to increase after 3 days
of treatment, and there was a 30% increase of p18-defi-
cient B cells over wild-type B cells (Fig. 4C). The in-
creased expansion of activated B cells in p18-null ani-
mals, both in vivo and in vitro, may have resulted from
an increase of cell proliferation or decrease of apoptosis
as B-cell activation is dynamically balanced by apoptosis
in the germinal centers. The percentage of cells under-
going apoptosis, following treatment with either CD40L
alone or CD40L together with IL-6, was comparable in
p18-null and wild-type B cells (Fig. 4D), indicating that a
decrease in apoptosis does not contribute significantly to
splenic hypercellularity. The increase in activated B
lymphocytes in the absence of p18 was therefore a con-
sequence of an increase in proliferation rate.
CD40 signaling alone can stimulate resting B cells to
enter the cell cycle. IL-6, although by itself does not pos-
sess mitogenic activity, can enhance the mitogenic
stimulatory effect of CD40L. Unexpectedly, stimulation
of p18-deficient resting B cells with CD40L alone, in the
absence of IL-6, resulted in a 2.5-fold increase in the
number of activated, viable IgM+ B cells over that of
wild-type cells, nearly approaching the proliferative rate
of wild-type resting B cells stimulated by both CD40L
and IL-6 (Fig. 4C). These results suggest that p18 has a
role in limiting the expansion of B-cell clones in vivo in
T-dependent humoral immune response and that a func-
tion for IL-6 in helping stimulate resting B cells with
CD40L may be to antagonize the inhibitory activity of
p18.
Figure 3. Hyperproliferative response of p18-deficient T
lymphocytes to mitogenic signals. (A) Flow cytometric
analysis of T lymphocytes. Cells from the thymus and
lymph nodes were isolated from 1-month-old animals and
CD4/CD8 profiles were determined. (B) Increased thymus
cellularity. Thymocytes were isolated from 1-month-old
wild-type (open bar) or p18-null (solid bar) animals, and cell
counts were obtained for each organ. (C) Apoptosis assay of
thymocytes in response to CD3. One-month-old wild-type
(left) and p18-null (right) animals were injected intraperi-
toneally with dexamethasone for 12 hr. Early apoptotic
cells were assayed by TdT end labeling and TdT–FITC FACS analysis. The percentage of apoptotic cells is indicated with standard
error. (D) In vitro and in vivo proliferation of lymph node cells. For the in vitro assay, lymph node cells were isolated from 1-month-old
wild-type (open bar) or p18-null (solid bar) animals and cultured in vitro. After ConA mitogenic stimulation, cells were pulsed with
[3H]thymidine. For in vivo stimulation, wild-type (open bar) and p18-null (solid bar) animals were injected intraperitoneally with ConA
for 12 hr. Cells were isolated from lymph nodes and immediately pulsed with [3H]thymidine. S-phase populations were determined
by measurement of 3H incorporation. (E) CDK4 and CDK6 kinase assay. Twelve hours after in vivo intraperitoneal ConA injection,
CDK4 and CDK6 complexes were immunoprecipitated from wild-type (open bars) or p18−/− (solid bars) lymph nodes and assayed for
their kinase activity with a GST–Rb fusion protein as substrate.
p18 and p18–p27 knockouts
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Progression of pituitary hyperplasia to adenoma
in mice lacking p18
In 15 of 15 examined p18−/− mice ranging from 4 weeks
to 13 months, the pituitary glands were enlarged com-
pared with those of p18+/+ control mice and displayed a
pattern of hyperplastic or neoplastic progression. Hyper-
plasia in the intermediate and anterior pituitary lobes
could be detected microscopically as early as 4 weeks in
p18−/− mice. As the p18-null mice aged, we detected in-
creasing hyperplasia in these lobes. Mild hyperplasia was
detected in 1- to 3-month-old p18−/− mice (n = 6), mod-
erate hyperplasia was detected in 4- to 8-month-old mice
(n = 5), and severe hyperplasia or an intermediate lobe
adenoma was found in 9- to 13-month-old mice (n = 4,
see below). Slight compression of the neurohypophysis
by the enlarged adenohypophysis was first detected at 5
and 6 months of age and compression became more pro-
nounced in 9- to 13-month-old p18−/− mice. Histologic
examination of a healthy looking 10-month-old p18−/−
mouse revealed severe intermediate lobe hyperplasia
(Fig. 5D,E). The anterior lobe was also enlarged in this
p18−/− mouse, but not to the same degree as the inter-
mediate lobe. No abnormal structures, such as atypical
cells, cystic structures, increased vascularity, or intersti-
tial hemorrhages, were detected in the pituitary of this
mouse, (data not shown).
PCNA staining of pituitary gland tissue in juvenile
animals (<6 weeks) was similar between p18+/+ and
p18−/−. Pituitary sections from a 6-week-old p18-null
animals showed minor increases in PCNA staining com-
pared with age-matched controls. In young p18−/− adults
(4–8 months), the pituitary was moderately enlarged and
reflected only minor increases in PCNA staining. How-
ever, in older animals (9–13 months), the pituitary was
greatly enlarged and was associated with a more pro-
nounced PCNA staining, particularly in animals that de-
velop intermediate lobe adenomas (see below).
Three of four 10-month-old or older p18−/− mice that
we followed were visibly ataxic, thin, and dehydrated.
Histologic examination of all three debilitated animals
revealed a large pituitary adenoma (Fig. 5G). The adeno-
mas originated from the intermediate lobe (Fig. 5H) and
the cells stained strongly for adrenocorticotropic hor-
mone (ACTH; Fig. 5I). These adenomas severely com-
pressed, but did not invade the adjacent anterior lobe,
though the neurohypophysis was always obliterated. A
hyperplastic nodule was also noted adjacent to one of the
adenomas and may have derived from the anterior lobe.
The intermediate lobe tumor and hyperplastic nodule
Figure 4. Hyperproliferative response of p18-deficient B lymphocytes to
mitogenic signals. (A) Flow cytometric analysis of B lymphocytes. Cells
from the bone marrow and spleen were isolated from 2-month-old ani-
mals, and IgM and B220 profiles were determined. (B) Increased cellularity.
Bone marrow and spleen were isolated from 2-month-old wild-type (open
bars) or p18-null (solid bars) animals, and cell counts were obtained for
each organ. (C) Mitogenic stimulation of B lymphocytes. Resting B lym-
phocytes were purified from p18+/+ (n) and p18−/− (j) spleens. A total of
1.5 × 105 cells/ml were cultured in vitro in the presence of CD40 ligand
[CD40L (n) p18+/+; (h) p18−/−] or in the presence of CD40L and IL-6 [(m)
p18+/+; (j) p18−/−]. Viable cells were determined every 24 hr by trypan blue
dye exclusion and expressed as viable cells per milliliter. (D) Apoptosis
assay of stimulated B cells. Resting B-lymphocyte populations were puri-
fied from wild-type and p18-null animals and cultured in the presence of
CD40L with or without IL-6. At day 5, cells were analyzed for early apop-
tosis with FITC-conjugated annexin V antibody and PI double staining.
Other time points were also normal between wild-type and p18-null cells.
Franklin et al.
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stained moderately for PCNA. These results indicate a
slow, age-dependent progression of the pituitary pheno-
type in p18-null mice: from mild intermediate lobe hy-
perplasia to moderate and severe hyperplasia associated
with increasing PCNA staining, compression of adjacent
lobes, and finally the development of an intermediate
lobe adenoma.
We compared pituitary ACTH expression in wild-type
and null animals by immunohistochemistry (Fig. 5C,F).
Immunostaining revealed uniform ACTH expression in
the intermediate lobe of p18−/− and p18+/+ mice. Plasma
levels of ACTH have not been determined. Because the
intermediate lobe of p18−/− mice is enlarged, it might be
postulated that an increase in serum ACTH levels could
contribute to the enlargement of the adrenal gland (Fig.
2D), specifically the adrenal cortex. However, there was
no histological evidence of adrenal cortical hyperplasia
(data not shown).
Loss of p18 function does not affect the level
of p27 and p27–CDK complexes
There are striking phenotypic similarities between mice
lacking p18 and those lacking p27 (Fero et al. 1996; Ki-
yokawa et al. 1996; Nakayama et al. 1996). Both mice are
developmentally normal, but display increased body
size, widespread organomegaly, multiple organ hyperpla-
sia, increased lymphocyte mitogenic responses and de-
velop spontaneous intermediate lobe pituitary lesions
with 100% penetrance. Two different mechanisms may
account for such phenotypic similarities. Either p18 and
p27 function on the same pathway in a upstream–down-
stream manner, and loss of one may lead to a decreased
expression or function of the other. Alternatively, p18
and p27 mediate two separate pathways, but converge on
common targets.
To distinguish these two mechanisms, we examined
the level of p27 expression and its complex formation
with the three G1 CDKs (CDK2, CDK4, and CDK6) in
p18-deficient cells. We chose the spleen and thymus for
this analysis as they are associated with hyperprolifera-
tive phenotypes in both p18- and p27-null animals. Total
protein lysates were prepared from both tissues from
wild-type and p18-null animals and analyzed for their
expression of CDK2, CDK4, and CDK6 as well as the
association of these CDKs with p27. The steady-state
levels of all three CDK proteins were not changed by the
loss of p18 in both tissues (Fig. 6A) as well as in several
other tissues that we examined (e.g., testis, data not
shown). The level of p27 protein was not changed by the
loss of p18 function, nor was its association with CDK2,
CDK4, and CDK6 (Fig. 6B).
p18 and p27 collaboratively suppress pituitary
tumor growth
Analysis of p27 expression and its association with the
CDK proteins indicated that p18 and p27 are unlikely to
act on the same pathway. To conclusively determine the
mechanism underlying the phenotypic similarities be-
tween p18- and p27-deficient mice, we generated mice
lacking both genes by crossing p18-null mice to mice
carrying a disruptive mutation in the cyclin–CDK inhi-
bition domain of p27 (Kiyokawa et al. 1996). Mating of
p18+/−; p27+/+ mice with p18+/+; p27+/− mice produced
all four genotypes in an essentially 1:1:1:1 Mendelian
ratio (4:5:6:4, respectively). Mating between the mice
heterozygous for both genes similarly produced all geno-
types with anticipated Mendelian ratios, indicating that
embryos with partial or complete loss of both p18 and
p27 function are viable. Mutations of both p18 and p27
genes in the double-mutant mice were determined by
Southern blotting (Fig. 6C) and verified further by exami-
nation of the expression of both proteins in pituitary
tissues (Fig. 6D).
Consistent with previous reports (Nakayama et al.
1996; Kiyokawa et al. 1996; Fero et al. 1996) and similar
to the phenotype seen in p18 mutant mice, in 20 p27-
null mice that we have examined between the ages of 1
Figure 5. Pituitary tumorigenesis in p18−/− mice. Pituitaries
from p18+/+ (healthy 10-month-old, A–C), p18−/− (healthy 10-
month-old with hyperplasia, D–F) and p18−/− (debilitated 9.5-
month-old with adenoma, G–I). (A,D,G) Comparative sizes of
pituitaries. Arrows indicate pituitaries. Bar, 1 mm. (B,E,H) His-
tological staining of the pituitaries. Cross sections of pituitaries
of p18+/+ (B) and p18−/− (E) and mid-sagittal section of p18−/−
mice (H) were stained with hematoxylin and eosin. (A) Anterior
lobe; (I) intermediate lobe; [I(T)] intermediate lobe tumor; and
(N) neurohypophysis. (*) Hyperplastic nodule. (Black bars)
Width of the intermediate lobe. Size bars, ∼70 µm for B and E
and 1 mm for H. (C,F,I) ACTH staining of pituitaries. Cross-
section of pituitaries of control p18+/+ (C) and p18−/− (F) and
mid-sagittal section of p18−/− mice (I) were stained for ACTH.
Abbreviations and symbols are as in other panels. Size bars, ∼70
µm for C and F and 1 mm for I.
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and 11 months, pituitary tumors were detected only in
the two oldest animals (8 and 11 months, respectively),
and not in the other 18 younger animals. Not a single
p27 mutant mouse died of a pituitary tumor. Mice lack-
ing both p18 and p27 functions initially appeared to be
developmentally normal. By three months they appear
visibly thin, ataxic, and dehydrated. All p18/p27 double-
deficient mice died by 3.5 months of pituitary tumors
(n = 17). In addition to the accelerated rate of pituitary
tumorigenesis, many organs, such as the spleen, thymus,
heart, testis, and adrenal gland, were more enlarged in
the p18/p27 double-null mice than in either p18- or p27-
deficient mice (data not shown). These observations pro-
vide genetic evidence that simultaneous loss of both p18
and p27 exaggerated the phenotype caused by the defi-
ciency of either single gene, indicating that these two
genes function in separate pathways to collaboratively
regulate cell growth. Because the pituitary tumorigen-
esis represents a well-characterized phenotype and can
be compared quantitatively by the rate of tumor progres-
sion, we focused our study on determining p18/p27 in-
teraction on pituitary tumor development. A detailed
characterization of the p18/p27 double-null mice will be
described elsewhere.
We examined the pituitaries from 1- and 3-month-old
wild-type, p18−/−, p27−/−, or p18−/−/p27−/− animals. Pi-
tuitaries from either p18- or p27-null animals at the
same age were comparable in size and were always larger
than age-matched wild-type controls (Fig. 7A). In addi-
tion, both possessed hyperplastic intermediate lobes
larger than wild-type animals (Fig. 7B). The histological
appearance of the pituitary gland of p18−/−/p27−/−
double-null animals was evidently different from either
single-null animal at the same age. The pituitaries from
1-month-old p18−/−/p27−/− animals were greatly en-
larged, and the intermediate lobe was more hyperplastic
than that of either single-null animal. The intermediate
lobe already stained moderately for PCNA, and the neu-
rohypophysis was slightly compressed. By 3 months,
p18−/−/p27−/− animals developed pituitary tumors com-
parable to 10-month-old p18-null or p27-null animals.
No p18−/−/p27−/− animal survived past 3.5 months—all
Figure 6. p27 and p27–CDK complexes in p18-deficient mice.
(A) Expression of G1 CDK2, CDK4, and CDK6 is unchanged in
p18-null cells. Total protein lysates were prepared from thy-
muses and spleens of wild-type or p18-null mice. The levels of
the three CDK and p18 proteins were determined by IP–Western
blot analysis with the indicated antisera. (B) p27–CDK com-
plexes were not affected in p18-null cells. Total protein lysates
prepared from thymuses and spleens of wild-type or p18-null
mice were precipitated with anti-p27 antibody, and the level of
p27 associated CDK proteins was determined by immunoblot-
ting. (C) Generation of p18−/−/p27−/− double-mutant mice.
Southern blot analysis of the p18 and p27 loci. Genomic DNA
from mice with four different genotypes was digested with
EcoRV (for p18) or EcoRI (for p27) and hybridized with a p18 and
a p27 probe as indicated. (D) Expression of p18 and p27 proteins
in mice pituitary. Equal amounts of total cell lysates prepared
from pituitary tissues of mice with four different genotypes
were resolved by SDS-PAGE. p18 and p27 protein levels were
determined by immunoblotting. The level of CDK4 protein re-
mains relatively constant in different genetic backgrounds and
was used as an additional control.
Figure 7. Pituitary tumorigenesis in p18−/−/p27−/− mice. (A)
Pituitaries from wild-type, p18−/−, p27−/−, and p18−/−/p27−/−
mice at 1 and 3 months were compared. (Arrows) Pituitaries.
Bars, 1 mm. Note the different size bar (also 1 mm) for the
pituitary from the 3-month-old p18−/−/p27−/− mouse. (B) Histo-
logical staining of wild-type, p18−/−, p27−/−, and p18−/−/p27−/−
pituitaries. Cross sections or mid-sagittal sections of pituitaries
of the four different genotypes were stained with hematoxylin
and eosin. (A) Anterior lobe; (I) intermediate lobe; and (N) neu-
rohypophysis. (Black bars) Width of the intermediate lobe. Size
bars, 70 mm, except for the pituitary from the 3-month-old
p18−/−/p27−/− mouse (1 mm).
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dying from pituitary adenomas. On the basis of invasion
into the adjacent nerves, one of the p18−/−/p27−/− ani-
mals was diagnosed with a pituitary carcinoma. This
synergistic response in p18/p27 double-null animals pro-
vides genetic evidence that p18 and p27 functionally col-
laborate to suppress pituitary tumor growth.
Discussion
Function of p18 in growth control
Mice lacking p18 develop gigantism and widespread or-
ganomegaly, indicating a broad role of p18 in the growth
control of many different cell types. Consistent with this
notion is the observation that the p18 gene is expressed
widely in multiple tissues (Fig. 1C, and Guan et al. 1994;
Franklin and Xiong 1996; Zindy et al. 1997; Phelps and
Xiong 1998). Despite widespread hyperplasia and organo-
megaly, loss of p18 function does not cause gross con-
genital defects and all organs displaying hyperplasia (e.g.,
the thymus and spleen) appear developmentally normal.
These observations indicate that p18 is not required for
cell viability and organomorphogenesis and that p18
does not have an essential role in causing the cell cycle
withdrawal during terminal cell differentiation. With-
drawal of mitogenic stimuli during terminal differentia-
tion still enables cell cycle arrest in p18-deficient cells as
in wild-type cells. Only when cells are challenged by
mitogenic stimuli, can the effect of p18 loss on cell
growth become evident. Cell cycle arrest brought about
during terminal cell differentiation is apparently domi-
nant over deregulated cell proliferation caused by the
loss of the growth-suppressive activity of p18.
Increase in organ size can be caused by either an in-
crease in cell number (hyperplasia), increase in indi-
vidual cell size (hypertrophy) or a decrease in apoptosis.
Examination of p18-deficient mice did not reveal any
cell type with abnormal hypertrophy. In both T lympho-
cytes and splenic B cells, there was no obvious decrease
in apoptosis (Figs. 4,5). Instead, in both the spleen and
thymus, the increase in the organ size correlated with an
increase in cell number. The mechanism underlying this
increase in the cell number caused by the loss of p18
function is not clear at present. It is conceivable that loss
of p18 function may shorten the G1 interval, leading to a
faster cell division cycle in precursor or progenitor cells,
thereby contributing to an increase in cell number prior
to the cell cycle withdrawal during terminal cell differ-
entiation.
Function of p18 in lymphocyte mitogenic activation
Optimal T- or B-cell activation requires stimulation
from at least two signals, such as CD3 and CD28 (or IL-2)
for T cells, or B-cell receptor (or IL-6) and CD40L for B
cells. CD40-activated B cells enter the cell cycle and can
be stimulated further by addition of cytokines (for a re-
cent review, see Van Kooten and Banchereau 1997). The
mechanism underlying the requirements for these two
signals is unknown. IL-6 is a pleiotropic cytokine that
can enhance the mitogenic activity of CD40L in stimu-
lating resting B cells to enter the cell cycle (Fig. 4). The
proliferation rate of p18-deficient B cells in response to
CD40L stimulation in the absence of IL-6 is similar to
that of wild-type B cells in response to co-stimulation by
CD40L and IL-6 (Fig. 4C). This finding provides genetic
evidence suggesting a role for p18 in negatively regulat-
ing G1 progression of B lymphocytes in response to
CD40L and a function for IL-6 in antagonizing the in-
hibitory activity of p18 in resting B-cell activation. We
further speculate that one function of the CD40 signal-
ing pathway is to activate cyclin D expression. Such
thinking would be consistent with the observation that
CD40 alone (after prolonged stimulation), but not IL-6, is
able to induce resting B cells into the cell cycle. Induc-
tion of cyclin D can eventually titrate off the p18-im-
posed block, but down-regulation of p18 in the absence
of D cyclins is apparently not sufficient to activate
CDK4/6. In principle, this mechanism can be utilized in
other mitogenic events such as T cell activation that also
requires two signaling pathways to achieve full activa-
tion.
p18 and p27 mediate two separate pathways
and collaborate functionally
Among the many phenotypic similarities shared be-
tween p18- and p27-deficient mice, perhaps the most
striking is the development of pituitary tumors. Not
only are the tumors in both mice of the same interme-
diate lobe origin, but they also progress at essentially the
same rate, succumbing to pituitary adenoma by ∼10–12
months. The function of both genes in suppressing pitu-
itary tumorigenesis is consistent with the observation
that both p18 and p27 proteins are highly expressed in
the pituitary tissues (Fig. 6D). The specificity of this
function is further underscored by the fact that mice
deficient for three other CDK inhibitor genes, p16 (Ser-
rano et al. 1996), p21 (Deng et al. 1995), and p57 (Zhang
et al. 1997; Yan et al. 1997) do not develop pituitary
anomalies.
Significantly, pituitary tumorigenesis in mice lacking
both p18 and p27 genes is greatly accelerated. Pituitary
adenomas can be detected histologically by 1 month and
all p18−/−/p27−/− mice die of pituitary tumors by 3.5
months (Fig. 6). This observed synergy provides the first
genetic evidence for a specific functional collaboration
between two CDK inhibitors. We have also crossed p18-
null mice with mice carrying a disrupted p21 CDK in-
hibitor gene (Deng et al. 1995). Unlike mice deficient for
both p18 and p27, mice lacking both p18 and p21 genes
do not develop pituitary tumors at any faster rate than
the mice lacking the p18 gene alone (D. Franklin and Y.
Xiong, unpubl.), further confirming and emphasizing the
specificity of functional collaboration between p18 and
p27. The biochemical mechanism underlying the func-
tional collaboration between p18 and p27 is not known
at present. Cooperation between CDK inhibitors has
been observed previously during antimitogenic cytokine
TGF-b-induced G1 cell cycle arrest (Reynisdottir et al.
p18 and p18–p27 knockouts
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1995; Reynisdottir and Massague 1997). p15, induced by
TGF-b, binds to CDK4/6, which coincides with a de-
crease (release) of CDK4/6-bound (sequestered) p27 and
an increase of CDK2–p27 association. These observa-
tions led to an interpretation that p15 and p27 function
in an upstream–downstream fashion on a single pathway
in which p15 acts genetically as a regulator of p27. Dur-
ing in vitro-induced myogenesis and adipogenesis, p18 is
significantly induced, yet, there is no detectable change
in the levels of p27–CDK2, p27–CDK4, and p27–CDK6
complexes (Franklin and Xiong 1996; Phelps and Xiong
1998). In this study, we compared the level of p27 and its
association with CDK2, CDK4, and CDK6 between
wild-type and p18-deficient cells from several tissues
that developed the overgrowth phenotype in the absence
of p18 and did not detect any obvious changes in p27–
CDK complexes (Fig. 6). Therefore, both genetic and bio-
chemical evidence argues against the possibility that p18
acts as an upstream regulator of p27 in a linear fashion.
Rather, these two genes appear to mediate two separate
pathways, and retaining both pathways is necessary to
completely suppress pituitary tumor growth (Fig. 8).
The only other gene whose loss of function resulted in
pituitary tumor formation is the retinoblastoma gene,
Rb (Jacks et al. 1992; Lee et al. 1992; Hu et al. 1994;
Robanus Maandag et al. 1994; Williams et al. 1994). The
biochemical functions of both p18 and p27 in inhibiting
CDK activity and the cell cycle-dependent phosphoryla-
tion of Rb by CDKs leads us to suggest further that Rb is
the common target of both p18- and p27-mediated tumor
suppression pathways in the pituitary (Fig. 8). Supporting
this notion is the observation that growth suppression by
p18, like p16, correlates with the wild-type Rb function
(Guan et al. 1994). Both the average age of pituitary tu-
mor manifestation (∼8–10 months) and its near complete
penetrance in heterozygous Rb mice are intriguingly
similar to those of p18 or p27 single-mutant mice (Hu et
al. 1994). The rate of pituitary tumorigenesis is greatly
accelerated in Rb chimeras, most of which succumb to
pituitary tumors at ∼4 months (Williams et al. 1994; Ro-
banus Maandag et al. 1994), and is almost the same as in
p18−/−/p27−/− mice.
Of the four INK4 CDK inhibitor genes, only p16INK4a
has been linked directly to tumor suppression despite its
product sharing almost indistinguishable biochemical
properties with the other three INK4 proteins. Frequent
genetic alteration of p16 and its three downstream
genes—cyclin D1, CDK4/6, and Rb—and the nonover-
lapping pattern of their mutations in different types of
human cancer has led to the hypothesis that p16–CDK4/
cyclin D1–Rb pathway may function as a common ge-
netic target in oncogenic transformation (Serrano et al.
1996; Sherr 1996). Notably, however, mice lacking p16
(and exon 2 of p19ARF), while developing spontaneous
tumors at multiple sites and at an early age, do not dis-
play any pituitary abnormality (Serrano et al. 1996). To-
gether with the observation that p18/p27 double-null
mice develop pituitary tumors at the same rate as Rb
chimeric mice, we conclude that, at least in the mouse,
it is not p16, but p18 and p27 that play the major role in
suppressing tumorigenesis in certain tissues by control-
ling the function of Rb.
Material and methods
Gene targeting and generation of null mice
A 19-kb murine p18INK4c genomic clone was isolated from a
129/Sv mouse genomic lFIXII library (Stratagene, La Jolla, CA)
by screening with a mouse p18 cDNA probe (Phelps et al. 1998).
The genomic clone was mapped by restriction digest analysis
and partially sequenced. A deletion targeting plasmid, p18KO,
derived from the pPNT vector (Tybulewicz et al. 1991), was
constructed by use of two p18 genomic fragments: a 4.6-kb
NotI–EcoRI and a 1.9-kb EcoRI–KpnI fragment. These fragments
flank a 2-kb EcoRI fragment containing p18 exon 3 (see Fig. 1A,
and Phelps et al. 1998). The resulting p18KO targeting vector
was electroporated into 129/Sv embryonic stem (ES) cells. Fifty
independent G418-resistant colonies were analyzed for p18 sta-
tus by Southern blot analysis with EcoRV-digested genomic
DNA hybridized with a 0.8-kb probe, which detects an ∼12-kb
fragment in the wild-type allele and a 9-kb fragment in the
targeted mutant allele. Targeted ES clones were verified further
with the same probe hybridized to SphI-digested genomic DNA
generating an ∼14-kb fragment in the wild-type allele and a
17-kb fragment in the targeted mutant allele. Two p18+/− ES
clones that karyotyped normal were microinjected into
C57BL/6 blastocysts and implanted into foster B6 females.
Eleven resulting F1 male chimeras were backcrossed to B6D2
females. Three of the chimeras, all derived from one of the ES
clones, transmitted agouti coat color via their germ line. Several
F2 heterozygotes were identified by Southern blot analysis and
mated to produce F3 wild-type, heterozygous, and p18-null lit-
termates, which were used as founders. Intercrosses have been
carried out to F6 and F7 without any alteration of the observed
phenotypes. The p27-null mice were derived from CJ7 p27 het-
erozygous ES cells also microinjected into C57BL/6 blastocysts
as described previously (Kiyokawa et al. 1996). Chimeric F1 p27
Figure 8. Suppression of pituitary tumorigenesis by p18 and
p27. p18 and p27 mediate two separate pathways to collabora-
tively suppress pituitary tumorigenesis. The upstream regula-
tory signals leading to the activation of p18 and p27 are un-
known. Rb is suggested to be the common target of p18 and p27
function on the basis of the observations that the biochemical
functions of p18 and p27 are to inhibit CDK activity regulating
pRb function and that chimeric Rb−/− mice and p18−/−/p27−/−
double-deficient mice develop pituitary tumors at essentially
the same rate.
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males were backcrossed with C57BL/6 females to produce F2
p27 heterozygotes. The p18/p27 double-null mice were derived
from crossing p18-null F3 mice with p27+/− mice. Mice were
genotyped, and the resulting F2 p18/p27 double heterozygotes
were intercrossed to create the double-null animal. Therefore,
all four genotypes (wild type, p18 null, p27 null and p18/p27
double null) were mostly B6 in their genetic background. All
genotypes were confirmed by Southern blot and verified by im-
munoblotting with antibodies specific to p18 or p27 proteins
(Figs. 1,6).
Anatomic and histologic analysis
To measure body weights, 18 (9 males and 9 females) wild-type
or p18-null mice were weighed every 6 days. Organs were iso-
lated and weighed from 1-, 2-, and 3-month old wild-type or
p18-null mice (three males and three females for each genotype
and time point). For histological analysis, tissues were fixed in
10% buffered formalin, dehydrated by use of increasing concen-
trations of ethanol, cleared in xylene, and embedded in paraffin.
Slides prepared with 5-µm sections were stained with hema-
toxylin and eosin.
Antibodies and immunochemistry
Antisera for p18, p27, CDK2, CDK4, and CDK6 (Xiong et al.
1993; Franklin and Xiong 1996), immunoprecipitations (IP), and
immunoblotting procedures have been described previously
(Jenkins and Xiong 1995). Protein lysate concentrations were
determined by Bradford assay and equalized for each experi-
ment. Kinase assays were performed as described previously
(Franklin and Xiong 1996; Phelps and Xiong 1997). PCNA im-
munohistochemistry was performed on formaldehyde-fixed pi-
tuitary sections from age-matched wild-type, p18-null, or p18/
p27 double-null mice. Hydrated tissue sections were rinsed in
PBS containing 1% Tween-20 (PBS-T). Hydrogen peroxide
quenching, PBS-T washes, staining with primary (mouse anti-
human PC10 antibody, 1:100 dilution, Dako Corp., Carpinteria,
CA) and secondary (goat anti-mouse IgG antibody, undiluted,
Dako Corp.) antisera, visualization by the chromogen 3838-di-
aminobenzidine (DAB) and counterstaining with hematoxylin
were performed according to methods provided in the Dako
Envision Kit (Dako Corp.). ACTH immunostaining was per-
formed on formaldehyde-fixed pituitary sections from 10-
month-old wild-type and p18-null mice. Hydrated tissue sec-
tions were rinsed in PBS and quenched 10 min in 3% hydrogen
peroxide solution in 100% methanol. Antigen retrieval was en-
hanced by heating sections in a microwave to 96°C for 8 min in
a citric acid buffer (1.8 mM citric acid, 8.2 mM sodium citrate).
Sections were blocked with 2% normal goat serum, stained
with primary (rabbit anti-human ACTH, Zymed Laboratories,
San Francisco) and secondary (goat anti-rabbit IgG, 1:200 dilu-
tion, Vector Laboratories, Inc.) antisera and visualized by the
chromogen DAB and counterstained with hematoxylin accord-
ing to methods provided in the Vectastain ABC kit (Vector
Laboratories, Inc.).
Bone marrow, lymph nodes, spleen, and thymus cells
Organs were obtained from wild-type or mutant animals and
transferred to PBS supplemented with 2% calf serum. Single cell
suspensions were prepared by squeezing organs between two
frosted microscope slides in RPMI-1640 media with 10% FBS.
Live cells (based on trypan blue exclusion) were counted on a
hemocytometer. Thymus cellularity was determined from six
wild-type and six p18-null (1-month-old) animals. Spleen cellu-
larity was determined from four wild-type and four p18-null
(2-month-old) animals. Bone marrow cellularity was deter-
mined from nine wild-type and nine p18-null (2-month-old) ani-
mals.
To analyze T-cell populations, cells obtained from the thy-
mus, lymph nodes, and spleen were stained with FITC-conju-
gated rat monoclonal antibody to mouse CD4 and phycoery-
thrin (PE)-conjugated rat antibody to mouse CD8 (Caltag Labo-
ratories). Splenic and bone marrow B cell populations were
measured by staining with FITC-conjugated goat antibody to
mouse IgM and PE-conjugated rat antibody to mouse CD45R
(B220; Caltag). Nonviable cells were excluded by propidium io-
dide (PI) staining and cell scatter profile. All FACS analyses
were carried out from a total of six wild-type and six p18-null
animals by use of the FACSCAN flow cytometer (Becton-Dick-
inson) and Cyclops 2000 version 4 data analysis software (Cy-
tomation).
For in vitro stimulation, 5 × 105 lymph node cells from 4-
week-old mice were cultured in 200 µl of RPMI-1640 medium
supplemented with 10% FBS, with or without 5 µg/ml ConA
(Sigma) in 96-well flat-bottom plates. After 54 hr, [3H]thymidine
(1 µCi per well, NEN) was added, and cells were cultured for an
additional 18 hr. Labeled cells were harvested, and incorporated
3H was measured by a liquid scintillation counter. The experi-
ment was performed using triplicate cultures from three wild-
type and three p18-mutant animals. To stimulate lymphocytes
in vivo, mice were injected intraperitoneally with 100 µg ConA
in 0.3 ml of sterile PBS. After 12 hr, mice were sacrificed, lymph
nodes were harvested and single cell suspensions were prepared.
Immediately, 8 × 105 cells were incubated with [3H]thymidine
in 96-well plates (1 µCi per well) for 12 hr at 37°C in RPMI-1640
supplemented with 10% FBS. The labeled cells were harvested,
and incorporated 3H was measured. The experiment was re-
peated twice with triplicate cultures from two wild-type and
two p18-null animals.
High density resting B lymphocytes isolated from the spleen
of 2-month-old wild-type or p18-null mice by Percoll gradient
centrifugation were cocultured (4.5 × 105 cells/p60 dish at a
density of 1.5 × 105 cells/ml) with mitotically arrested L cells
expressing the mouse CD40L. In separate cultures, the B lym-
phocytes were co-cultured with L cells expressing mouse
CD40L in the presence of recombinant IL-6 (40 U/ml) synthe-
sized in baculovirus as described previously (Morse et al. 1997).
The soluble IL-6 receptor gp80 synthesized in baculovirus (40
U/ml) was also added to enhance the formation of the high-
affinity IL-6 receptor. The biological activity of IL-6 and soluble
gp80 was determined by induction of B-lymphocyte terminal
differentiation in CESS cells (Morse et al. 1997). Viable cells
were counted after trypan blue staining every 24 hr for 6 days.
The experiment was repeated three times with triplicate cul-
tures from two wild-type and two p18-null animals.
Apoptosis assay
Three wild-type and three p18-null (4-week-old) mice were used
for the in vivo T-lymphocyte apoptosis assays. Two wild-type
and two p18-null animals were injected intraperitoneally with
dexamethasone for 12 hr (0.5 mg of dexamethasone in 0.3 ml of
sterile PBS). One wild-type animal and one p18-null animal
were injected with 0.3 ml of sterile PBS as mock controls.
Mouse thymocytes were harvested as described above. Apop-
totic cells were assayed by terminal deoxynucleotide transfer-
ase (TdT) end labeling analysis as described previously (Su et al.
1995). Resting B-lymphocyte populations were purified from
four wild-type and four p18-null animals and cultured in dupli-
cate in the presence of CD40L with or without IL-6 as detailed
p18 and p18–p27 knockouts
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above. At each time point, cells were analyzed for early apop-
totic cells with FITC-conjugated annexin V antibody and PI
double staining according to methods provided in the Apoptosis
Detection kit (Oncogene Research Products, Inc., Cambridge,
MA).
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